Methods and compositions for treating polycystic ovary syndrome

Details Methods and compositions for treating polycystic ovary syndrome Methods and compositions for treating polycystic ovary syndrome

2006-09-12

2006-09-12

Russel, Jeffrey Edwin (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S012200

Reexamination Certificate

active

07105490

ABSTRACT:
The present invention relates to methods of treating polycystic ovary syndrome (PCOS) comprising administering glucagon-like peptide-1 (GLP-1), exendin, and analogs and agonists thereof, to subjects suffering therefrom.

REFERENCES:
patent: 6329403 (2001-12-01), Odaka et al.
patent: 6569901 (2003-05-01), Mogensen et al.
patent: 6610746 (2003-08-01), Fryburg et al.
patent: 2002/0137666 (2002-09-01), Beeley et al.
patent: 2004/0029874 (2004-02-01), Hathaway
patent: 2004/0029891 (2004-02-01), Ghazzi et al.
patent: 2004/0180824 (2004-09-01), Knudsen
Ahles, “Toward a New Approach: Primary and Preventive Care of the Woman with Polycystic Ovarian Syndrome”,Prim. Care Update Ob/Gyns., 7(6):275-278 (2000), U.S. Appl. No. 10/317,126.
Balen, “Ovulation Induction for Polycystic Ovary Syndrome”,Human Fertility, 3:106-111 (2000), U.S. Appl. No. 10/317,126.
Barbieri, “Induction of Ovulation in Infertile Women with Hyperandrogenism and Insulin Resistance”,Am. J. Obstet. Gynecol., 183(6):1412-1418 (2000), U.S. Appl. No. 10/317,126.
Ciampelli and Lanzone, “Insulin and Polycystic Ovary Syndrome: a New Look at an Old Subject”,Gynecol. Endocrinol., 12:277-292 (1998), U.S. Appl. No. 10/317,126.
Conway, “Hyperinsulinaemia and Polycystic Ovary Syndrome”,Human Fertility, 3:93-95 (2000), U.S. Appl. No. 10/317,126.
Davison, “New Approaches to Insulin Resistance in Polycystic Ovarian Syndrome”,Current Opinion in Obstetrics and Gynecology, 10:193-198 (1998), U.S. Appl. No. 10/317,126.
Ehrmann, “Relation and Functional Ovarian Hyperandrogenism to Non-Insulin Dependent Diabetes Mellitus”,Bailliére's Clinical Obstetrics and Gynaecology, 11(2):335-347 (1997), U.S. Appl. No. 10/317,126.
Franks, “Polycystic Ovary Syndrome”,Medical Progress, 333(13):853-861 (1995), U.S. Appl. No. 10/317,126.
Franks et al., “Insulin Action in the Normal and Polycystic Ovary”,Endocrinology and Metabolism Clinics of North America, 28(2):361-378 (1999), U.S. Appl. No. 10/317,126.
Hadine et al., “Editorial: Polycystic Ovarian Syndrome—Relationship to Epilepsy and Antiepileptic Drug Therapy”,J. Clin. Endocrinology&Metabolism, 86(7):2946-2949 (2001), U.S. Appl. No. 10/317,126.
Hopkinson et al., “Polycystic Ovarian Syndrome: the Metabolic Syndrome Comes to Gynaecology”,BMJ, 317:329-332 (1998), U.S. Appl. No. 10/317,126.
Iuorno et al., “Insulin-Lowering Drugs in Polycystic Ovary Syndrome”,Obstetrics and Gynecology Clinics of North America, 28(1):153-164 (2001), U.S. Appl. No. 10/317,126.
Kim et al., “Insulin Sensitizers and Polycystic Ovary Syndrome: Can a Diabetes Medication Treat Infertility?”,Fertility and Sterility, 73(6):1097-1098 (2000), U.S. Appl. No. 10/317,126.
Legro, “Polycystic Ovary Syndrome: Current and Future Treatment Paradigms”,Am. J. Obstet. Gynecol., 179(6), part 2, pp. S101-S108 (1998), U.S. Appl. No. 10/317,126.
Nestler, “Role of Hyperinsulinemia in the Pathogenesis of the Polycystic Ovary Syndrome, and Its Clinical Implications”,Seminars in Reproductive Endocrinology, 15(2):111-122 (1997), U.S. Appl. No. 10/317,126.
Olefsky and Saltiel, “PPARγ and the Treatment of Insulin Resistance”,TEM, 11(9):362-367 (2000), U.S. Appl. No. 10/317,126.
Phipps, “Polycystic Ovary Syndrome and Ovulation Induction”,Obstetrics and Gynecology Clinics of North America, 28(1):165-182 (2001), U.S. Appl. No. 10/317,126.
Pugeat and Ducluzeau, “Insulin Resistance, Polycystic Ovary Syndrome and Metformin”,Drugs, 58 Suppl. 1:41-46 (1999), U.S. Appl. No. 10/317,126.
Rosenfield, “Current Concepts of Polycystic Ovary Syndrome”,Bailliére's Clinical Obstetrics and Gynaecology, 11(2):307-333 (1997), U.S. Appl. No. 10/317,126.
Spiegelman, “PPARγ in Monocytes: Less Pain, Any Gain?”,Cell, 93:153-155 (1998), U.S. Appl. No. 10/317,126.
Udoff and Adashi, “Polycystic Ovarian Disease: A New Look at an Old Subject”,Current Opinion in Obstetrics and Gynecology, 7:340-343 (1995), U.S. Appl. No. 10/317,126.
Utiger, “Insulin and the Polycystic Ovary Syndrome”,The New England Journal of Medicine, 335(9):657-658, (Aug. 29, 1996), U.S. Appl. No. 10/317,126.
Wolf, “Ovulation Induction”,Clinical Obstetrics and Gynecology, 43(4):902-915 (2000), U.S. Appl. No. 10/317,126.
Zacur, “Polycystic Ovary Syndrome, Hyperandrogenism, and Insulin Resistance”,Obstetrics and Gynecology Clinics of North America, 28(1):21-33 (2001), U.S. Appl. No. 10/317,126.

Affiliated with

Also associated with

Rating

Methods and compositions for treating polycystic ovary syndrome does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods and compositions for treating polycystic ovary syndrome, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for treating polycystic ovary syndrome will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3547786